Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer
暂无分享,去创建一个
D. Groheux | P. Merlet | M. Espié | C. Sotiriou | P. de Cremoux | L. Biard | M. Resche-Rigon | J. Lehmann-Che | L. Teixeira | P. Bertheau | F. Bouhidel | P. Crémoux | B. Poirot | Luis Teixeira
[1] F. Couch,et al. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups , 2016, Breast Cancer Research.
[2] I. Ellis,et al. Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer , 2016, Diagnostic Pathology.
[3] Matthieu Resche-Rigon,et al. 18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen , 2016, The Journal of Nuclear Medicine.
[4] Keda Yu,et al. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer , 2016, Oncotarget.
[5] D. Groheux,et al. 18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[6] Alexandre Cochet,et al. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer , 2015, Clinical Cancer Research.
[7] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[8] M. Hatt,et al. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. , 2014, European journal of cancer.
[9] H Tesch,et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] H. Sasano,et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy , 2013, Breast Cancer Research and Treatment.
[11] C. Perou,et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] C. Sotiriou,et al. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] D. Groheux,et al. Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer , 2012, Journal of the National Cancer Institute.
[14] Stefan Michiels,et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Gelber,et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Patrick Royston,et al. Visualizing and assessing discrimination in the logistic regression model , 2010, Statistics in medicine.
[17] Benjamin Haibe-Kains,et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues , 2009, BMC Genomics.
[18] C. Sotiriou,et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[20] S. Rodenhuis,et al. Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[21] Gang Huang,et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis , 2011, Breast Cancer Research and Treatment.